COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
Status:
Completed
Trial end date:
2015-08-19
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are (i) to select an oral modified release (MR)
formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults
with heart failure and left ventricular systolic dysfunction and (ii) to characterize its
pharmacokinetics (PK) over 20 weeks of treatment.